Benjamin Arnold1, Sandra A Mitchell2, Lauren Lent1, Tito R Mendoza3, Lauren J Rogak4, Natalie M Barragán4, Gordon Willis5, Mauricio Medina6, Suzanne Lechner7, Frank J Penedo8, Jay K Harness9, Ethan M Basch4,10. 1. FACITtrans, LLC, 381 S. Cottage Hill Ave, Elmhurst, IL, 60126, USA. 2. Division of Cancer Control and Population Sciences, Outcomes Research Branch, National Cancer Institute, 9609 Medical Center Drive, East Tower, Room 3-448, Rockville, MD, 20850, USA. mitchlls@mail.nih.gov. 3. Department of Symptom Research, The University of Texas M. D. Anderson Cancer Center, 1400 Pressler Street, Unit 1450, Houston, TX, 77030, USA. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA. 5. Division of Cancer Control and Population Sciences, Behavioral Research Program, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD, 20850, USA. 6. Health Education and Digital Information Dissemination Branch, Office of Science Policy, Engagement, Education and Communications (OSPEEC), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. 7. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1120 NW 14 Street, C202, Miami, FL, 33136, USA. 8. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 633 N., St. Clair, USA. 9. The Center for Cancer Prevention and Treatment, St. Joseph Hospital of Orange, 1010 West La Veta Avenue, Suite 470, Orange, CA, 92868, USA. 10. Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Campus Box 7305, Chapel Hill, NC, 27599, USA.
Abstract
PURPOSE: The U.S. NCI's PRO-CTCAE is a library of self-report items for assessing symptomatic adverse events in cancer clinical trials from the patient perspective. The aim of this study was to translate and linguistically validate a Spanish version. METHODS: PRO-CTCAE's 124 items were translated from English into Spanish using multiple forward and back translations. Native Spanish speakers undergoing cancer treatment were enrolled at six cancer treatment sites. Participants each completed approximately 50 items and were then interviewed using cognitive probes. The interviews were analyzed at the item level by linguistic themes, and responses were examined for evidence of equivalence to English. Items for which ≥20 % of participants experienced difficulties were reviewed, and phrasing was revised and then retested in subsequent interviews. Items where <20 % of respondents experienced difficulties were also reviewed and were considered for rephrasing and retesting. RESULTS: One hundred nine participants from diverse Spanish-speaking countries were enrolled (77 in Round 1 and 32 in Round 2). A majority of items were well comprehended in Round 1. Two items presented difficulties in ≥20 % of participants and were revised/retested without further difficulties. Two items presented difficulties in <20 %, and when retested exhibited no further difficulties. Two items presented difficulties in <20 %, but were not revised due to lack of alternatives. Sixteen items presented difficulties in ≤12 % and were not revised because difficulties were minor. CONCLUSIONS: The Spanish PRO-CTCAE has been developed and refined for use in Spanish-speaking populations, with high levels of comprehension and equivalence to the English PRO-CTCAE. TRIAL REGISTRATION: ClinicalTrials.gov:NCT01436240.
PURPOSE: The U.S. NCI's PRO-CTCAE is a library of self-report items for assessing symptomatic adverse events in cancer clinical trials from the patient perspective. The aim of this study was to translate and linguistically validate a Spanish version. METHODS: PRO-CTCAE's 124 items were translated from English into Spanish using multiple forward and back translations. Native Spanish speakers undergoing cancer treatment were enrolled at six cancer treatment sites. Participants each completed approximately 50 items and were then interviewed using cognitive probes. The interviews were analyzed at the item level by linguistic themes, and responses were examined for evidence of equivalence to English. Items for which ≥20 % of participants experienced difficulties were reviewed, and phrasing was revised and then retested in subsequent interviews. Items where <20 % of respondents experienced difficulties were also reviewed and were considered for rephrasing and retesting. RESULTS: One hundred nine participants from diverse Spanish-speaking countries were enrolled (77 in Round 1 and 32 in Round 2). A majority of items were well comprehended in Round 1. Two items presented difficulties in ≥20 % of participants and were revised/retested without further difficulties. Two items presented difficulties in <20 %, and when retested exhibited no further difficulties. Two items presented difficulties in <20 %, but were not revised due to lack of alternatives. Sixteen items presented difficulties in ≤12 % and were not revised because difficulties were minor. CONCLUSIONS: The Spanish PRO-CTCAE has been developed and refined for use in Spanish-speaking populations, with high levels of comprehension and equivalence to the English PRO-CTCAE. TRIAL REGISTRATION: ClinicalTrials.gov:NCT01436240.
Authors: Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring Journal: Value Health Date: 2011-10-10 Impact factor: 5.725
Authors: Michelle K Wilson; Deborah Collyar; Diana T Chingos; Michael Friedlander; Tony W Ho; Katherine Karakasis; Stan Kaye; Mahesh K B Parmar; Matthew R Sydes; Ian F Tannock; Amit M Oza Journal: Lancet Oncol Date: 2014-12-29 Impact factor: 41.316
Authors: A E Bonomi; D F Cella; E A Hahn; K Bjordal; B Sperner-Unterweger; L Gangeri; B Bergman; J Willems-Groot; P Hanquet; R Zittoun Journal: Qual Life Res Date: 1996-06 Impact factor: 4.147
Authors: Ethan M Basch; Bryce B Reeve; Sandra A Mitchell; Stephen B Clauser; Lori Minasian; Laura Sit; Ram Chilukuri; Paul Baumgartner; Lauren Rogak; Emily Blauel; Amy P Abernethy; Deborah Bruner Journal: Cancer J Date: 2011 Jul-Aug Impact factor: 3.360
Authors: Ethan Basch; Amy P Abernethy; C Daniel Mullins; Bryce B Reeve; Mary Lou Smith; Stephen Joel Coons; Jeff Sloan; Keith Wenzel; Cynthia Chauhan; Wayland Eppard; Elizabeth S Frank; Joseph Lipscomb; Stephen A Raymond; Merianne Spencer; Sean Tunis Journal: J Clin Oncol Date: 2012-10-15 Impact factor: 44.544
Authors: Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch Journal: Qual Life Res Date: 2013-07-20 Impact factor: 4.147
Authors: Bryce B Reeve; Sandra A Mitchell; Amylou C Dueck; Ethan Basch; David Cella; Carolyn Miller Reilly; Lori M Minasian; Andrea M Denicoff; Ann M O'Mara; Michael J Fisch; Cynthia Chauhan; Neil K Aaronson; Corneel Coens; Deborah Watkins Bruner Journal: J Natl Cancer Inst Date: 2014-07-08 Impact factor: 13.506
Authors: Bryce B Reeve; Molly McFatrich; Laura C Pinheiro; David R Freyer; Ethan M Basch; Justin N Baker; Janice S Withycombe; Lillian Sung; Jennifer W Mack; Mia K Waldron; Catriona Mowbray; Diana Palma; Pamela S Hinds Journal: J Pain Symptom Manage Date: 2017-01-03 Impact factor: 3.612
Authors: Siu-Fun Wong; Joseph M Unger; James L Wade; Lynne I Wagner; Mario E Lacouture; Keisha C Humphries; Anna Moseley; Kathryn Arnold; Mario R Velasco; Justin D Floyd; Benjamin T Esparaz; Afsaneh Barzi; Heinz-Josef Lenz; Marianna Koczywas; Shaker Dakhil; Gary V Burton; Michael J Fisch; N Lynn Henry; Dawn L Hershman; Carol M Moinpour Journal: J Patient Rep Outcomes Date: 2020-07-08
Authors: Mark A Samaan; Polychronis Pavlidis; Sophie Papa; Nick Powell; Peter M Irving Journal: Nat Rev Gastroenterol Hepatol Date: 2018-03-07 Impact factor: 46.802